Generate Biomedicines, Inc.
- GENB · Nasdaq
- Pharmaceutical Preparations
- Somerville, MA
- CIK 0002100782
Updated from SEC filings through
Top things to know
Executives
- Michael Nally Chief Executive Officer 4, 2026-03-06
- Jason Silvers President & CFO 4, 2026-03-02
- Gevorg Grigoryan Chief Technology Officer 4, 2026-03-02
- Sean Martin Chief Legal Officer & GC 4, 2026-03-02
- Beth Grous Chief People Officer 4, 2026-03-02
- Laurie Anne Lee Chief Medical Officer 4, 2026-03-02
What leadership is saying
“Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicines drove strong progress in the second quarter”
Earnings press release (8-K Ex. 99.1), filed August 6, 2026
Generate Biomedicines, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Somerville, MA. It trades as GENB on Nasdaq. Michael Nally is Chief Executive Officer.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Michael Nally | Chief Executive Officer | 4, 2026-03-06 |
| Jason Silvers Generate Biomedicines | President & CFO | 4, 2026-03-02 |
| Gevorg Grigoryan Co-Founder and CTO at Generate Biomedicines, Inc. | Chief Technology Officer | 4, 2026-03-02 |
| Sean Martin Chief Legal Officer and General Counsel | Chief Legal Officer & GC | 4, 2026-03-02 |
| Beth Grous | Chief People Officer | 4, 2026-03-02 |
| Laurie Anne Lee | Chief Medical Officer | 4, 2026-03-02 |
| Aarif Khakoo Physician-scientist, drug developer, and biotech executive | Chief Scientific Officer | 3, 2026-02-26 |
What Generate Biomedicines, Inc. does
We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies.
Item 1. Business, 10-K for the year ending February 27, 2026
Shares and governance
| Shares outstanding | 128.4 million (as of July 29, 2026) | 10-Q, August 6, 2026 |
|---|
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 29, 2026 | Frances Arnold Director | Sale | 11,409 | $185K | Form 4, November 4, 2026 |
| September 1, 2026 | Frances Arnold Director | Sale | 1,000 | $16K | Form 4, September 3, 2026 |
| March 4, 2026 | Michael Nally Chief Executive Officer | Buy | 20,000 | $240K | Form 4, March 6, 2026 |
| March 2, 2026 | Beth Grous Chief People Officer | Buy | 300 | $5K | Form 4, March 2, 2026 |
| March 2, 2026 | Jason Silvers President & CFO | Buy | 2,000 | $32K | Form 4, March 2, 2026 |
| March 2, 2026 | Noubar Afeyan Director | Buy | 4,687,500 | $75.0M | Form 4, March 2, 2026 |
| March 2, 2026 | Jane L. Mendillo Director | Buy | 1,500 | $24K | Form 4, March 2, 2026 |
| March 2, 2026 | Noubar Afeyan Director | Buy | 4,687,500 | $75.0M | Form 4, March 2, 2026 |
Recent 8-K events
- 8-K filed 2026-08-26
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-02
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Generate Biomedicines, Inc.
- What does Generate Biomedicines, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies."
- Who is the CEO of Generate Biomedicines, Inc.?
- Michael Nally, Chief Executive Officer, as named in a 4 filed March 6, 2026.
- Who is the CFO of Generate Biomedicines, Inc.?
- Jason Silvers, President & CFO, as named in a 4 filed March 2, 2026.
- Where is Generate Biomedicines, Inc. headquartered?
- Somerville, MA.
- What is Generate Biomedicines, Inc.'s stock ticker?
- GENB on Nasdaq.
- What industry is Generate Biomedicines, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Generate Biomedicines, Inc.'s website?
- generatebiomedicines.com. Investor relations: https://investors.generatebiomedicines.com/.
- When does Generate Biomedicines, Inc. report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Generate Biomedicines, Inc. a public company?
- Yes. Generate Biomedicines, Inc. files with the SEC under CIK 0002100782 and trades as GENB.
- How many shares of Generate Biomedicines, Inc. are outstanding?
- 128.4 million shares as of July 29, 2026, from its 10-Q filed August 6, 2026.
- Have Generate Biomedicines, Inc. insiders traded stock recently?
- Since March 2, 2026, officers and directors reported 2 open-market sales worth about $201K and 6 purchases worth about $150M on Forms 4 and 5. The most recent: Frances Arnold (Director) sold 11,409 shares on October 29, 2026.